News archive
Showing 702 results
October 2013
-
Media Release
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
Every 30 seconds, someone in the US is hospitalized for heart failure1; mobile solutions could play a role to help manage this disease Novartis Mobile Health Challenge attracted… -
Media Release
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
September 2013
-
Media Release
Novartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
Study result signals potential kidney benefit with RLX030;1 future studies will further explore this impact Kidney dysfunction affects approximately 30 percent of US heart failure… -
Media Release
Novartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
June 2013
-
Media Release
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease
- Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer's; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6… -
Media Release
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease
-
Media Release
TV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign
-- "Together in MS" tandem teams have pedaled 1,000 miles in 15 National MS Society "Bike MS" events since 2011-- Campaign pairs pro women's cyclists and people with MS to raise awareness of multiple… -
Media Release
TV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign
May 2013
-
Media Release
Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
-- At six months, adjusted mean treatment satisfaction scores increased by a statistically significant 20.4 with Gilenya vs. 2.9 with injectable disease modifying therapies1-- In one of the largest… -
Media Release
Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
-
Media Release
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
- Latest Phase III research on Afinitor® in advanced HER2 positive breast cancer- Jakavi™ overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-…